|
TRIO expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.05239999995221E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.24209999999392E-05 |
| Normal-vs-Stage2 |
8.25100000000356E-05 |
| Normal-vs-Stage3 |
1.122450E-03 |
| Normal-vs-Stage4 |
1.796040E-03 |
| Stage1-vs-Stage2 |
7.242600E-01 |
| Stage1-vs-Stage3 |
6.053200E-01 |
| Stage1-vs-Stage4 |
9.939800E-01 |
| Stage2-vs-Stage3 |
4.682000E-01 |
| Stage2-vs-Stage4 |
7.808600E-01 |
| Stage3-vs-Stage4 |
7.359800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.37949999999776E-05 |
| Normal-vs-AfricanAmerican |
1.260350E-02 |
| Normal-vs-Asian |
4.178400E-04 |
| Caucasian-vs-AfricanAmerican |
9.972000E-01 |
| Caucasian-vs-Asian |
4.984400E-01 |
| AfricanAmerican-vs-Asian |
6.345200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.30460000000866E-05 |
| Normal-vs-Female |
4.14989999997228E-06 |
| Male-vs-Female |
7.607200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.409650E-04 |
| Normal-vs-Age(41-60Yrs) |
1.46450000004794E-06 |
| Normal-vs-Age(61-80Yrs) |
5.87669999999596E-05 |
| Normal-vs-Age(81-100Yrs) |
2.400400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.795000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.657800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.094600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.644400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.883000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.427600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.680400E-01 |
| Classical-VS-Follicular |
1.83130000053211E-07 |
| Classical-VS-Other |
4.643600E-01 |
| Classical-VS-Normal |
2.661200E-03 |
| Tall-VS-Follicular |
4.508200E-02 |
| Tall-VS-Other |
6.533000E-01 |
| Tall-VS-Normal |
4.097900E-02 |
| Follicular-VS-Other |
3.887800E-01 |
| Follicular-VS-Normal |
3.43539641178836E-11 |
| Other-VS-Normal |
3.354400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.64829999982352E-07 |
| Normal-vs-N1 |
5.679100E-03 |
| N0-vs-N1 |
1.721820E-01 |
|
|
